Phase 2/3 human trials on the Oxford-AstraZeneca vaccine candidate by the Serum Institute of India (SII) were also underway in the country until last week, when they had to be paused after a trial participant in the UK developed an unexplained adverse reaction.
Posted from: this blog via Microsoft Flow.
No comments:
Post a Comment